https://www.avient.com/products/engineered-polymer-formulations/high-temperature-polymer-formulations/compl%C4%93t-long-fiber-reinforced-structural-thermoplastics Off-road vehicle manufacturer

https://www.avient.com/products/engineered-polymer-formulations/eco-conscious-formulations/nymax-post-industrial-recycled OEM automotriz destacado

Glucose Monitoring App Snapshot draft M E D I C A L D E V I C E O E M C O N T I N U O U S G L U C O S E M O N I T O R I N G S Y S T E M • Adapt to strict processing requirements of a secondary operation put in place to manufacture a new device model • Meet material size and thickness requirements while achieving desired color target • Overcome material unpredictability and sensitivity to heat, light and moisture • Minimize impact of supply chain instability and changes • Offered support for processing under low pressure conditions and at every stage of manufacturing • Performed extensive R&D work to consistently deliver the customer’s color target of a hard-to-achieve light gray • Effectively addressed all material challenges and sensitivities • Provided regular ‘summaries of understanding’ to keep up with changing forecasts and ordering patterns Mevopur™ Pre-color Formulation KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/polymer-colorants/solid-color-masterbatches/mevopur-custom-colors-and-formulations

L E A D I N G M E D I C A L T R A I N I N G C O M PA N Y M E D I C A L M A N I K I N S • Ability to color code various body parts for more accurate teaching and instruction • Maintain durability and performance through repeated use in a variety of training scenarios • Meet customer’s regulatory requirements • Provided specific colors and hardness for easier identification of body parts • Supplied a non-phthalate plastisol formulation that maintained strength and flexibility over an extended time • Offered robust technical support and regulatory assistance to meet all compliance directives as required by customer Core™ Non-Phthalate Plastisols KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/vinyl-formulations/vinyl-plastisols-organosols/core-non-phthalate-plastisols

M E D I C A L E Q U I P M E N T M A N U FA C T U R E R C L O S E D S Y S T E M D R U G T R A N S F E R D E V I C E • A new material for a seal inside the next generation of closed system drug transfer device • Compliance with stringent regulatory standards: • Biocompatibility to ISO10993 • USP VI compliance • Provided regulatory support services and expertise throughout extensive medical approval process • Provided a custom formulation compliant with the highest healthcare regulatory standards • Enabled material to be manufactured and shipped globally Custom Versalloy™ HC 9220-90 Formulation KEY REQUIREMENTS WHY AVIENT?

S I D IN G & C LA D D I N G M A N U FAC T U R E R P R O F I L E E X T R U S I O N • Achieve consistent distribution and uniform cell structure • Avoid adverse chemical reactions caused by material incompatibility with PVC formulations • Maintain impact resistance and durability • Attain thermally-stable chemical foaming agent (CFA) and gas decomposition temperatures to avoid manufacturing downtime • Ensure the integrity of color, finish, and aesthetics • Validated performance and compatibility during formulation and testing to confirm material compatibility and consistency • Established processing parameters for real- time precision in temperature, pressure, and extrusion speed • Optimized CFA and process to balance weight reduction and retain mechanical properties and aesthetics Hydrocerol Chemical Foaming Agents KEY REQUIREMENTS WHY AVIENT?

Medical textile manufacturer LEARN MORE MEDICAL TEXTILE MANUFACTURER S U R G I C A L D R A P E S & G O W N S • Pre-tested for ISO 10993 biocompatibility standard • Available in standard blue or other customized colors • Compatible with ETO sterilization • Suitable for use in non-woven SMS spunbond layer • Offered standard blue and custom colors such as green • Pre-tested raw materials for biocompatibility ISO10993 standard • Manufactured under ISO 13485 certified medical sites with change control in place MevopurTM Healthcare Colorants and Formulations KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/polymer-colorants/healthcare-colorants/mevopur-healthcare-colorants-and-formulations Slide 1: Medical textile manufacturer

https://www.avient.com/products/engineered-polymer-formulations/high-temperature-polymer-formulations/compl%C4%93t-long-fiber-reinforced-structural-thermoplastics

Conference Call As previously announced, the company will conduct a conference call to discuss its financial results for the third quarter at Comptek, SilCoTec, Gordon Composites and Polystrand, including whether such businesses will be accretive, retain the management teams of acquired businesses, and retain relationships with customers of acquired businesses; disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; our ability to achieve new business gains; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; changes in polymer consumption growth rates and laws and regulations regarding the disposal of plastic in jurisdictions where we conduct business; changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online; fluctuations in raw material prices, quality and supply and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to working capital reductions, cost reductions and employee productivity goals; an inability to raise or sustain prices for products or services; our ability to continue to pay cash dividends, including at the increasing rate, which will be subject to, among other factors, market conditions, our cash flow and cash requirements and restrictions contained in any of our debt agreements; and other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation.

As previously announced, the company will conduct a conference call to discuss its financial results for the first quarter Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: our ability to realize anticipated savings and operational benefits from the realignment of assets, including the closure of manufacturing facilities; the timing of closings and shifts of production to new facilities related to asset realignments and any unforeseen loss of customers and/or disruptions of service or quality caused by such closings and/or production shifts; separation and severance amounts that differ from original estimates; amounts for non-cash charges related to asset write-offs and accelerated depreciation realignments of property, plant and equipment that differ from original estimates; our ability to identify and evaluate acquisition targets and consummate acquisitions; the ability to successfully integrate acquired businesses into our operations, including whether such businesses will be accretive, retain the management teams of acquired businesses, and retain relationships with customers of acquired businesses; disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the financial condition of our customers, including the ability of customers (especially those that may be highly leveraged and those with inadequate liquidity) to maintain their credit availability; the speed and extent of an economic recovery, including the recovery of the housing market; our ability to achieve new business gains; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; changes in polymer consumption growth rates and laws and regulations regarding the disposal of plastic in jurisdictions where we conduct business; changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online; fluctuations in raw material prices, quality and supply and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to working capital reductions, cost reductions and employee productivity goals; an inability to raise or sustain prices for products or services; an inability to maintain appropriate relations with unions and employees; our ability to continue to pay cash dividends; the amount and timing of repurchases of our common shares, if any; and other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation.